VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/32317203/

⇱ Cardiovascular complications in COVID-19 - PubMed


Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
πŸ‘ Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

πŸ‘ Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

Background: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur.

Objective: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection.

Discussion: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications.

Conclusions: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19.

Keywords: Acute myocardial infarction; COVID-19; Cardiovascular; Dysrhythmia; Heart failure; Infectious disease; Myocarditis; Troponin.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None.

Figures

πŸ‘ Fig. 1
Fig. 1
COVID-19 and the cardiovascular system.

Comment in

  • Cardiovascular complications in COVID-19.
    Butt N, Arshid A, Ahmad SA, Khalid N, Kayani WT. Butt N, et al. Am J Emerg Med. 2021 Jul;45:540. doi: 10.1016/j.ajem.2020.07.032. Epub 2020 Jul 19. Am J Emerg Med. 2021. PMID: 32713605 Free PMC article. No abstract available.

References

    1. World Health Organization WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-rem... Available online at.
    1. Coronavirus Disease 2019 (COVID-19) Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
    1. World Health Organization Situation report. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
    1. Driggin E., Madhavan M.V., Bikdeli B. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. Mar 18 2020 [pii: S0735-1097(20)34637-4, in press] - PMC - PubMed
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Feb 24 2020 doi: 10.1001/jama.2020.2648. [Epub ahead of print] - DOI - PubMed
Cite

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.